HFCWO in Children With Non-CF Bronchiectasis

July 22, 2026 updated by: Marwa El-kawy Ghait Mohamed, Sphinx university

Effect of High Frequency Chest Wall Oscillation on Pulmonary Functions in Children With Non-Cystic Fibrosis Bronchiectasis

the study will concentrate on the effect of High Frequency Chest Wall Oscillation compared to conventional pulmonary physiotherapy on children with non cystic fibrosis bronchiectasis

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of this study is to evaluate the effect of using HFCWO intervention on pulmonary functions in children with bronchiectasis.

it hypothesized that Using HFCWO has no effect on pulmonary functions and hospital stay in children with bronchiectasis.

Children subjected to the inclusion criteria will be assigned randomly into two groups, control group and study group.

Does high frequency chest wall oscillation (HFCWO) have an effect in pulmonary functions in children with bronchiectasis? RCT study Control group Patients in this group will be 30 children who will be treated by conventional physiotherapy program directed towards improvement of pulmonary functions and quality of life.

Study group This group will include 30 children who will use HFCWO for 20 minutes, in addition to 10 minutes of the same conventional program of physiotherapy given to the control group.

The frequency of treatment will be 5 sessions/week for three successive months for both groups for long term effect and daily for immediate effect.

outcome measure: FEV1, FVC, FEV1/FVC quality of life for bronchiectasis, 6-minute walk test

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Children with no cystic fibrosis bronchiectasis

    • Both sexes
    • Their ages ranges from 6-12 years
    • After 48 hours of attack, if hemoptysis or fever not found

Exclusion Criteria:

  • • Osteoporosis (Calcium deficiency)

    • Bleeding tendency
    • Recent surgery of brain, eye, thoracic, or neck surgery
    • Pneumothorax
    • Cystic fibrosis bronchiectasis
    • Pulmonary embolism
    • Rib fracture

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: children who will use HFCWO for 20 minutes, in addition to 10 minutes of the same conventional progr

This group will include 30 children who will use HFCWO for 20 minutes, in addition to 10 minutes of the same conventional program of physiotherapy given to the control group.

The frequency of treatment will be 5 sessions/week for three successive months for both groups for long term effect and daily for immediate effect.
Device: High Frequency Chest Wall Oscillation

High-frequency chest wall oscillation that applies external chest wall oscillations via an inflatable vest worn around the thoracic cage, increasing the air-liquid shear forces during expiration is believed to result in secretion mobilization.

The product name that will be used is Air Way Clearness system; his model is PV-900/ PV-300/PV-100, made in China.
Active Comparator: children who will be treated by conventional physiotherapy program
Patients in this group will be 30 children who will be treated by conventional physiotherapy program directed towards improvement of pulmonary functions and quality of life.
Other: conventional physiotherapy program directed towards improvement of pulmonary functions and quality of life.

conventional physiotherapy program directed towards improvement of pulmonary functions and quality of life.

Conventional physiotherapy that will be applied to the control group for 30 minutes will include:

  • Postural drainage according to accumulation of secretions for 10 minutes accompanied by percussion or vibration
  • Active cycle breathing technique (ACBT) for 10 minutes
  • Respiratory exercises for 10 minutes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Forced Expiratory Volume in 1 second (FEV1)
Time Frame: Baseline and after 8 weeks of treatment
Change in FEV1 measured by spirometry according to ATS/ERS guidelines
Baseline and after 8 weeks of treatment
Forced Vital Capacity (FVC)
Time Frame: Baseline and after 6 months of treatment
Change in FVC measured by spirometry according to ATS/ERS guidelines
Baseline and after 6 months of treatment
FEV1/FVC Ratio
Time Frame: Baseline and after 6 months of treatment
Change in FEV1/FVC ratio measured by spirometry according to ATS/ERS guidelines
Baseline and after 6 months of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Six-Minute Walk Distance (6MWD)
Time Frame: Baseline and after 6 months of treatment
hange in functional exercise capacity assessed by the Six-Minute Walk Test (6MWT). The total distance walked in six minutes is recorded according to the American Thoracic Society (ATS) guidelines.
Baseline and after 6 months of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sphinx university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

June 2, 2026

First Submitted That Met QC Criteria

July 22, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 22, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HFCWO and bronchectasis

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non Cystic Fibrosis Bronchiectasis

Clinical Trials on High Frequency Chest Wall Oscillation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe